MaxCyte, Inc. (MXCT)
NMS · Healthcare · Medical Devices
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 8.5M | 6.8M | 7.3M | 9.7M |
| Gross Profit | 7.0M | 5.2M | 5.7M | 8.1M |
| Operating Income | -14.2M | -11.1M | -7.7M | -6.2M |
| Net Income | -12.4M | -12.4M | -9.6M | -4.8M |
| Diluted EPS | $-0.12 | $-0.12 | $-0.09 | $-0.04 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 44.3M | 41.3M | 38.6M | 33.0M |
| Gross Profit | 39.2M | 36.5M | 31.5M | 26.8M |
| Operating Income | -27.4M | -48.3M | -51.2M | -45.3M |
| Net Income | -23.6M | -37.9M | -41.1M | -44.6M |
| Diluted EPS | $-0.23 | $-0.37 | $-0.39 | $-0.42 |